Feb 18, 26

Luka Pavlekovic Appointed Director of Corporate and Legal Affairs at INA Grupa

INA Grupa has appointed Luka Pavlekovic its new Director of Corporate and Legal Affairs.

Pavlekovic has been with the organization for more than 16 years, originally joining as Contracting Specialist II in 2008 – a role he held until 2009. Between 2010 and 2014, he was the Director of Domestical Legal Affairs Department. He then worked as Head of Legal Affairs between 2014 and 2020. 

Prior to moving in-house and joining INA Grupa, Pavlekovic worked as a Lawyer at Law Firm Hrabar between 2004 and 2008.

Pavlekovic has also been a Member of the Supervisory Board at Energopetrol d.d. Sarajevo since 2014. His other board positions in the past included Member of the Supervisory Board at Petrol Plc. Jurdani between 2011 and 2020 and President of the Management Board at Terme Zagreb Ltd. between 2013 and 2019.

“I am excited to share that I have recently started a new role as Director of Corporate and Legal Affairs at Ina, Plc.,” commented Pavlekovic. “In this role, I will continue to manage legal and compliance issues, while also taking on corporate strategy, ESG, investor relations, and public affairs. This is a unique and rewarding challenge that I am really looking forward to.”

Get the memo – every week

Essential in-house updates, straight to your inbox.

Former Indotek Group Head of Legal Agnes Fabry Returns to Private Practice as Lakatos, Koves and Partners Of Counsel

Former Indotek Head of Legal M&A Agnes Farby has joined Lakatos, Koves and Partners as Of Counsel. She will work across the real estate, corporate and M&A, and banking and finance practices.

Irina Roxana Petre Joins Wolf Theiss as Partner

Former Engie Deputy Legal Director Irina Roxana Petre has joined Wolf Theiss as a Partner in the firm's Energy Industry Group in Romania.

Betfair Romania Development Hires Maria Muresan as the Head of Legal RO, PT, BG, IN

Prior to moving to Flutter Entertainment's technology hub, Muresan spent more than seven years at Novo Nordisk.